Virtual Library

Start Your Search

Chan Kwon Park



Author of

  • +

    P2.10 - Prevention and Tobacco Control (ID 176)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Prevention and Tobacco Control
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.10-03 - Prevalence of Tobacco Use Disorder in Patients Diagnosed with Lung Cancer and Their Tobacco Use Characteristics (Now Available) (ID 1108)

      10:15 - 18:15  |  Presenting Author(s): Chan Kwon Park

      • Abstract
      • Slides

      Background

      Tobacco use disorder (TUD), previously termed as nicotine dependence, was associated with increased risk of lung cancer. However, little is known about the prevalence of TUD and symptom manifestation in smokers with lung cancer. The aim of the present study was to investigate the prevalence of TUD using DSM-5 diagnostic criteria in patients diagnosed with lung cancer and determine their tobacco use characteristics.

      Method

      A total of 200 histologically confirmed lung cancer patients who used tobacco within prior 12-month period at the time of diagnosis were recruited for this study. Participants were assessed with interviewer-administered questionnaires on symptoms of TUD and smoking-related behaviors and self-administered Fagerstrom Test for Nicotine Dependence (FTND).

      Result

      The prevalence of DSM-5 TUD was 92.0% (n = 184). Of a total of 200 subjects, 23 (11.5%), 35 (17.5%), and 126 (63.0%) were classified as mild, moderate, and severe TUD, respectively. A total of 19 (81.3%) moderate TUD and 98 (77.8%) severe TUD patients had attempted smoking cessation. Of these subjects, 21 (21.4%) severe TUD patients and 12 (63.2%) moderate TUD patients had tried more than three times. The number of satisfied criteria of DSM-5 TUD was positively correlated with FTND score, cumulative lifetime smoking amount, and daily smoking amount.

      Conclusion

      Smokers diagnosed with lung cancer had high prevalence of DSM-5 TUD. Their heavy and consistent tobacco use characteristics might be less motivated to maintain abstinence and make them to be less stick to quit.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.17 - Treatment of Early Stage/Localized Disease (ID 189)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment of Early Stage/Localized Disease
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.17-17 - Clinical Effect of Adjuvant Chemotherapy on Stage IB NSCLC with High-Risk Factors (ID 2089)

      10:15 - 18:15  |  Author(s): Chan Kwon Park

      • Abstract

      Background

      The efficacy of adjuvant chemotherapy in stage IB NSCLC with high-risk factors remains unclear. We analyze the clinical effect of adjuvant chemotherapy in patients with high-risk factors such as visceral pleural involvement, and micro-papillary type, etc.

      Method

      This study is a multicenter retrospective study. We retrospectively analyzed 269 stage IB NSCLC with high-risk factors receiving lung resection operation from four academic hospitals. We defined the high-risk factors as visceral pleural invasion, vascular invasion, peri-neural invasion, lymphatic invasion, neuroendocrine tumors, and micro-papillary pattern. We used a Kaplan-Meier survival curve to analyze recurrence-free survival and overall survival.

      Result

      There were 139 (51.7%) males and 130 (48.3%) females and the mean patient age was 65.6 ± 9.7 years. There were 142 patients without adjuvant chemotherapy and 127 patients with adjuvant chemotherapy. The median follow-up duration was 31.7 months (range, 2.7 to 60.0 months). And the recurrence-free survival was 48.8 ± 1.8 months in the no adjuvant group, and 54.0 ± 1.5 months in the adjuvant group (P=0.028). And the overall survival was 57.9 ± 0.9 months in the no adjuvant group, and 59.3 ± 0.7 months in the adjuvant group (P=0.124). In the sub-group analysis (visceral pleural involvement group), the recurrence-free survival was 48.2 ± 2.1 months in the no adjuvant group, and 55.3 ± 1.6 months in the adjuvant group (P=0.011)

      Conclusion

      Adjuvant chemotherapy may be useful for patients with Stage IB NSCLC with high-risk factors. And, adjuvant chemotherapy should be considered especially when there is visceral pleural involvement